H-1B sponsorship profile: Celldex Therapeutics. Across U.S. Department of Labor LCA disclosures, Celldex Therapeutics filed 3 Labor Condition Applications covering 3 H-1B worker positions between fiscal year 2024 and fiscal year 2026. The employer’s DOL certification rate sits at 100% (3 certified of 3 filed), a useful proxy for how cleanly their prevailing-wage attestations pass the Labor Department’s preliminary review before USCIS adjudication.

Compensation spread. Offered wages on Celldex Therapeutics’s H-1B petitions range from $140,000 at the low end to $195,000 at the high end, with a petition-weighted average of $163,042. That range reflects the mix of occupations the company sponsors, led by Senior Manager, Quality Control (1 petitions at $154,125 avg), followed by Manager, Drug Substance and Associate Director, Regulatory Affairs. H-1B salaries reported on LCAs must meet or exceed the DOL prevailing wage for the role and worksite, so the spread also tracks wage-level geography and seniority.

Geographic footprint. Celldex Therapeutics is headquartered in Hampton, NJ under NAICS code 541714, and places H-1B workers across 3 states, most heavily in CT, MA, NJ. Combined, these signals give a granular view of how one employer uses the H-1B program, volume, approval cleanliness, wage posture, and where the jobs actually sit on the map.

Where Celldex Therapeutics ranks. By H-1B petition volume, Celldex Therapeutics is #37,433 of 119,880 employers nationally and #2,485 of 5,818 employers headquartered in NJ. Both ranks are computed live from the same underlying petition counts, not a separate estimate.